1	Im	proved limit of detection for zoonotic <i>Plasmodium knowlesi</i> and <i>P. cynomolgi</i>
2	sur	veillance using reverse transcription for total nucleic acid preserved samples
3	or	dried blood spots
4		
5	Kar	nil A Braima ^{1*} , Kim A Piera ^{1*} , Inke ND Lubis ^{1,2} , Rintis Noviyanti ³ , Giri S Rajahram ^{5,6,7} ,
6	Pin	kan Kariodimedjo ⁴ , Irbah RA Nainggolan ² , Ranti Permatasari ² , Leily Trianty ³ , Ristya
7	Am	alia ⁴ , Sitti Saimah binti Sakam ⁵ , Angelica F Tan ^{1,5} , Timothy William ^{5,6} , Jacob AF
8	We	staway ^{1,8} , PingChin Lee ^{9,10} , Sylvia Daim ¹¹ , Henry Surendra ^{12,13} , Nathaniel Christy ¹⁴ ,
9	And	drew G Letizia ¹⁴ , Christopher L Peatey ¹⁵ , Mohd Arshil Moideen ¹⁶ , Bridget E Barber ^{1,5,17} ,
10	Col	in J Sutherland ¹⁸ , Nicholas M Anstey ^{1,5} , Matthew J Grigg ^{1,5}
11	*Eq	ual contribution
12		
13	Aff	iliations
14	1.	Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University,
15		Darwin, Northern Territory, Australia
16	2.	Faculty of Medicine, Universitas Sumatera Utara, Medan, Sumatera Utara, Indonesia
17	3.	Eijkman Research Center for Molecular Biology, BRIN, Indonesia
18	4.	Exeins Health Initiative, Jakarta, Indonesia
19	5.	Infectious Diseases Society Kota Kinabalu Sabah-Menzies School of Health Research Clinical Research
20		Unit, Kota Kinabalu, Sabah, Malaysia
21	6.	Clinical Research Centre-Queen Elizabeth Hospital, Ministry of Health, Kota Kinabalu, Sabah, Malaysia
22	7.	School of Medicine and Health Sciences, Monash University Malaysia, Kuala Lumpur, Malaysia
23	8.	Centre for Tropical Bioinformatics and Molecular Biology, James Cook University, Cairns, Queensland,
24		Australia
25	9.	Biotechnology Research Institute, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia.
26	10.	Faculty of Science and Natural Resources, Universiti Malaysia Sabah, Kota Kinabalu, Sabah Malaysia.

11 Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 28 12. Monash University Indonesia, Tangerang, Indonesia
- 29 13. Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta,
- 30 Indonesia
- 31 14. U.S. Naval Medical Research Unit INDO PACIFIC, Singapore
- 32 15. Drug Resistance and Diagnostics, Australian Defence Force Malaria and Infectious Disease Institute,
- 33 Brisbane, Queensland, Australia
- 34 16. Malaysian Armed Forces and Faculty of Medicine & Defence Health, National Defence University of
 35 Malaysia
- 36 17. QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
- 37 18. Department of Infection Biology, London School of Hygiene & Tropical Medicine, London, United
 38 Kingdom
- **39 Corresponding authors:**
- 40 Matthew Grigg, Global Health Division, Menzies School of Health Research, Rocklands
- 41 Drive, Tiwi, NT 0810, Australia. Email: <u>matthew.grigg@menzies.edu.au</u>
- 42
- 43 Inke ND Lubis, Faculty of Medicine, Universitas Sumatera Utara, Jl. Dr. Mansyur No.5,
- 44 Padang Bulan, Kec. Medan Baru, Kota Medan, Sumatera Utara 20155, Indonesia. Email:
- 45 <u>inkenadia@gmail.com</u>
- 46
- Key words: zoonotic malaria, *Plasmodium, P. knowlesi, P. cynomolgi, P. vivax*, PCR, reverse
 transcription, limit of detection, dried blood spots
- 49
- 50 Short title: Reverse transcription improves detection of *P. knowlesi* and *P. cynomolgi*
- 51
- 52
- 53

54 ABSTRACT

55 Background:

56 Zoonotic *P. knowlesi* and *P. cynomolgi* symptomatic and asymptomatic infections occur across 57 endemic areas of Southeast Asia. Most infections are low-parasitemia, with an unknown 58 proportion below routine microscopy detection thresholds. Molecular surveillance tools 59 optimizing the limit of detection (LOD) would allow more accurate estimates of zoonotic 60 malaria prevalence.

61 Methods:

An established ultra-sensitive *Plasmodium* genus quantitative-PCR (qPCR) assay targeting the 18S rRNA gene underwent LOD evaluation with and without reverse transcription (RT) for *P. knowlesi*, *P. cynomolgi* and *P. vivax* using total nucleic acid preserved (DNA/RNA ShieldTM) isolates and archived dried blood spots (DBS). LODs for selected *P. knowlesi*-specific assays, and reference *P. vivax-* and *P. cynomolgi*-specific assays were determined with RT. Assay specificities were assessed using clinical malaria samples and malaria-negative controls.

68 **Results:**

69 The use of reverse transcription improved *Plasmodium* species detection by up to 10,000-fold 70 (Plasmodium genus), 2759-fold (P. knowlesi), 1000-fold (P. vivax) and 10-fold (P. cvnomolgi). 71 The median LOD with RT for the Kamau et al. Plasmodium genus RT-qPCR assay was 72 ≤ 0.0002 parasites/µL for *P. knowlesi* and 0.002 parasites/µL for both *P. cynomolgi* and *P.* 73 vivax. The LODs with RT for P. knowlesi-specific PCRs were: Imwong et al. 18S rRNA 74 (0.0007 parasites/µL); Divis et al. real-time 18S rRNA (0.0002 parasites/µL); Lubis et al. hemi-75 nested SICAvar (1.1 parasites/µL) and Lee et al. nested 18S rRNA (11 parasites/µL). The LOD 76 for P. vivax- and P. cynomolgi-specific assays with RT were 0.02 and 0.20 parasites/µL 77 respectively. For DBS *P. knowlesi* samples the median LOD for the *Plasmodium* genus qPCR

with RT was 0.08, and without RT was 19.89 parasites/uL (249-fold change); no LOD
improvement was demonstrated in DBS archived beyond 6 years. The *Plasmodium* genus and *P. knowlesi*-assays were 100% specific for *Plasmodium* species and *P. knowlesi* detection,
respectively, from 190 clinical infections and 48 healthy controls. Reference *P. vivax*-specific
primers demonstrated known cross-reactivity with *P. cynomolgi*.

83 Conclusion:

Our findings support the use of an 18S rRNA *Plasmodium* genus qPCR and species-specific nested PCR protocol with RT for highly-sensitive surveillance of zoonotic and human *Plasmodium* species infections.

87

88 Author Summary:

89 The monkey malaria parasite Plasmodium knowlesi has been found to increasingly infect 90 humans across Southeast Asia via the bite of it's anopheline mosquito vectors. Human 91 infections with a similar monkey parasite, *Plasmodium cynomologi*, have also been reported. 92 The diagnostic tools commonly used to detect these malaria species are often unable to detect 93 very low-level infections. We aimed to to improve surveillance detection tools and blood 94 sample collection methods to detect these zoonotic malaria species and understand the extent 95 of transmission and the burden of disease. This study validated and compared the use of 96 molecular laboratory assays targeting these species. We found that with the use of reverse 97 transcription, large improvements in the limit of detection were possible, by up to 10,000-fold 98 for initial malaria screening, and up to 2759-fold for specific P. knowlesi detection. Findings 99 from this study support the use of ultrasensitive detection tools to improve surveillance 100 approaches to emerging zoonotic malaria species.

101

102 BACKGROUND

103 Plasmodium knowlesi is a unicellular protozoan malaria parasite present across Southeast Asia 104 within the geographical range of its natural monkey hosts and vector mosquitoes (1,2). P. 105 knowlesi is the most common cause of human malaria in Malaysia; capable of causing severe 106 disease comparable to P. falciparum (3-5). Human infections with other genetically similar 107 zoonotic species, such as *P. cynomolgi* which share the same natural macaque hosts, have also 108 been reported (6). Accurate detection of emerging zoonotic species such as *P. knowlesi* and *P.* 109 cynomolgi in co-endemic areas with other human Plasmodium species infections is necessary 110 to understand the geographical extent of zoonotic malaria transmission and to improve regional 111 estimates of the disease burden (7). Improving national malaria control program detection and 112 reporting of low-level P. knowlesi infections is also vital to demonstrate World Health 113 Organization (WHO)-certified elimination for other non-zoonotic malaria species in Southeast 114 Asia (8).

115 Conventional malaria diagnostic methods such as microscopy lack sensitivity and specificity 116 for active surveillance of P. knowlesi due to common low-level sub-microscopic infections and 117 an inability to accurately distinguish other morphologically similar *Plasmodium* species (7,9); 118 notably P. malariae and the early ring stages of P. falciparum (10,11). Similarly, P. cynomolgi 119 microscopically resembles P. vivax in human infections (12,13). Current malaria rapid 120 diagnostic tests which detect circulating Plasmodium species antigens also remain 121 insufficiently sensitive for P. knowlesi passive case detection at the low parasite counts able to 122 produce symptomatic infections (14-16). Multiple molecular methods to detect P. knowlesi 123 have been developed, including both quantitative and conventional qualitative PCR assays 124 (7,17). However, systematic comparisons of the lower limit of detection (LOD) of these assays 125 and exhaustive testing of *Plasmodium* species-specificity are currently lacking (7). The degree to which the LOD is enhanced with a prior reverse transcription (RT) step is not well
characterised despite potential benefits in improving the detection of very low-level
parasitemia symptomatic or asymptomatic zoonotic *Plasmodium* species infections (18).
Specificity for *P. knowlesi* detection also ideally needs to be validated against other macaque
zoonotic *Plasmodium* species, including *P. cynomolgi* (7).

To support an improved molecular surveillance workflow for detection of low-level zoonotic *Plasmodium* species infections (7,19), we evaluated an established *Plasmodium* genus and species-specific PCR assays with the inclusion of a reverse transcription step to enhance the LOD in both total nucleic acid preserved media and dried blood spot (DBS) collected samples.

136 METHODS

137 Clinical specimen collection and storage

138 Clinical venous whole blood samples and dried blood spots were collected prior to antimalarial 139 treatment from individuals diagnosed with malaria by routine hospital microscopy, as part of 140 an ongoing prospective malaria study in Sabah, Malaysia between April 2013 and May 2023. 141 Adult healthy individuals were recruited as malaria-negative controls. Additional P. vivax 142 clinical cases were enrolled from a prospective malaria study in western Indonesia between Jan 143 2022 and Aug 2023. Whole blood samples were collected in ethylenediaminetetraacetic acid (EDTA) and a small subset in DNA/RNA ShieldTM (Zymo Research, Irvine, CA, USA) before 144 145 being frozen at -80°C at the time of enrolment. DBS were concurrently made using 20µL whole 146 blood spotted on Whatman 3M filter paper and then stored in sealed bags with desiccant. A 147 single donated P. cynomolgi-infected sample (20) obtained from a macaque host was frozen in glycerolyte and stored in liquid nitrogen prior to thawing, counting and immediately placing in 148 DNA/RNA ShieldTM. 149

150 Microscopic parasite count quantification

151 Microscopic diagnosis of *Plasmodium* species was undertaken by experienced research 152 microscopists using thick and thin Giemsa-stained blood films. Microscopic quantification of 153 parasitemia (parasites per microlitre) was performed using thick blood smears calculated from 154 the number of parasites per 200 white blood cells, multiplied by the individual patient's total 155 white cell count obtained from routine hospital laboratory flow cytometry (21).

156 Total nucleic acid extraction and PCR amplification

157 Total nucleic acids were directly extracted from 200 µL of whole blood using a QIAamp® 158 DNA Blood Mini Kit (OIAGEN, Cat. No. 51106), with DNA/RNA ShieldTM samples eluted 159 in 50ul AE buffer to account for the preservative dilution factor. DNA and RNA extraction 160 from DBS were carried out using an in-house method, established by Zainabadi et al, 2017 161 (22). Briefly, DBS equivalent to 40µl whole blood was incubated with 900µl lysis buffer at 65°C, with shaking at 250rpm for 90 minutes. Lysate was transferred to QIAamp® DNA Blood 162 163 Mini Kit (QIAGEN, Cat. No. 51106) columns, washed with modified buffers, dried at 65°C 164 for 10 minutes and eluted in 40µl buffer AE. The primers, annealing temperatures and/or probe 165 sequences for each PCR assay are described in Table 1. Real-time PCR amplifications were performed on a QuantStudio[™] 6 Flex (Applied Biosystems). Conventional PCR was performed 166 on a DNA thermal cycler (Bio-Rad T100[™] thermal cycler). The amplified nested PCR products 167 168 were separated by electrophoresis using 2% agarose gels, stained by SYBR Safe™ 169 (Invitrogen), and visualised on a UV transilluminator (Gel Doc XR+ imaging system, Bio-170 Rad). Each PCR amplification included a *Plasmodium* species positive and negative control and molecular weight standards (Applied BiosystemsTM). 171

Table 1. Primer sequences and annealing temperatures of *Plasmodium* genus and species-specific PCR assays 173

Assay ID	PCR assays	Primer / Probe	Sequence (5' – 3')	Annealing temp. (°C)	PCR method	<i>Plasmodium</i> gene target
	Kamau et al, 2011 (26)	KamGF	GCTCTTTCTTGATTTCTTGGATG	60	RT-qPCR	18S rRNA
Plasmodium	(rRNA template)	KamGR	AGCAGGTTAAGATCTCGTTCG			
spp. screening		KamGP probe	FAM-ATGGCCGTTTTTAGTTCGTG-BHQ1			
Test A (Pk)	Divis et al, 2010 (27)	Plasmo 1	GTTAAGGGAGTGAAGACGATCAGA	60	qPCR	18S rRNA
		Plasmo 2	AACCCAAAGACTTTGATTTCTCATAA			
		Pk probe	FAM-CTCTCCGGAGATTAGAACTCTTAGATTGCT-BHQ1			
Test B (Pk)	Lubis et al, 2017 (29)	SICAfl	GGTCCTCTTGGTAAAGGAGG	55	Hemi-nested	SICAvar
		SICAr1	CCCTTTTTGACATTCGTCC			
		SICAf2	CTTGGTAAAGGAGGACCACG			
		SICAr1	CCCTTTTTGACATTCGTCC			
Test C (Pk)	Lee et al, 2011 (25)	rPLU 1	TCAAAGATTAAGCCATGCAAGTGA			
		rPLU 5	CCTGTTGTTGCCTTAAACTTC			
		Knlf	CTCAACACGGGAAAACTCACTAGTTTA	66	Nested	18S rRNA
		Kn3r	GTATTATTAGGTACAAGGTAGCAGTATGC			
Test D (Pcyn)	Lee et al, 2011 (25)	CY2F	GATTTGCTAAATTGCGGTCG	66		
		CY4R	CGGTATGATAAGCCAGGGAAGT			
Pk reference	Imwong et al, 2009 (24)	PkF1160	GATGCCTCCGCGTATCGAC	55	Hemi-nested	18S rRNA
		PkF1150	GAGTTCTAATCTCCGGAGAGAAAAGA			
		PkF1140	GATTCATCTATTAAAAATTTGCTTC	50		
		PkR1150	GAGTTCTAATCTCCGGAGAGAAAAGA			
Human- species	Snounou et al. (1993) (23)	rPLU6	TTAAAATTGTTGCAGTTAAAACG	58	Nested	18S rRNA
reference		rPLU5	CCTGTTGTTGCCTTAAACTTC			
		rFAL 1	TTAAACTGGTTTGGGAAAACCAAATATATT			
		rFAL 2	ACACAATGAACTCAATCATGACTACCCGTC			
		rVIV 1	CGCTTCTAGCTTAATCCACATAACTGATAC			
		rVIV 2	ACTTCCAAGCCGAAGCAAAGAAAGTCCTTA			
		rMAL 1	ATAACATAGTTGTACGTTAAGAATAACCGC			
		rMAL 2	AAAATTCCCATGCATAAAAAATTATACAAA			
		rOVA 1	ATCTCTTTTGCTATTTTTAGTATTGGAGA			
		rOVA 2	GGAAAAGGACACATTAATTGTATCCTAGTG			

175 *Plasmodium* species confirmation using reference PCR

176 A validated reference PCR targeting the *Plasmodium* 18S rRNA genes was used to confirm the 177 Plasmodium species using EDTA-whole blood clinical samples, consisting of an initial 178 Plasmodium genus (hereafter abbreviated to P. genus) nest 1, followed by species-specific nest 179 2 for P. falciparum, P. vivax, P. malariae, and P. ovale spp. (23). The P. knowlesi-(24) and P. 180 cynomolgi-specific (25) reference assays used also target 18S rRNA genes. The P. knowlesi 181 reference assay has a previously reported high sensitivity (LOD less than 10 parasite genomes) 182 when validated without reverse transcription (RT) against four P. knowlesi strains (Malayan, 183 H, Philippine, and Hackeri); specificity was assessed against the major human Plasmodium 184 species in addition to other simian *Plasmodium* species present in Southeast Asia including *P*. 185 cynomolgi, P. inui, and P. simiovale (24).

186 Selection of PCR assays for LOD evaluation

187 A reverse transcriptase real-time hydrolysis probe (RT-qPCR) assay designed to detect the P. 188 lasmodium genus was evaluated for its utility in enhancing LOD (Figure 1A) (26). Three 189 published P. knowlesi species-specific assays, which have not previously had their LODs 190 evaluated using reverse transcription, were compared to the reference assay (Figure 1B). Test 191 A is a qPCR assay (27) in current use in the State Public Health Laboratory (Makmal Kesihatan 192 Awam; MKA) Sabah, Malaysia, for routine P. knowlesi malaria detection (28). Test B is a 193 hemi-nested PCR targeting the multicopy SICAvar genes, previously validated for P. knowlesi 194 detection against P. falciparum, P. vivax, P. malariae, and P. ovale spp., in addition to clinical 195 P. knowlesi isolates from Sarawak, Malaysia (29). Test C is a nested conventional PCR assay 196 targeting 18S rRNA genes specific for *P. knowlesi* that has been robustly validated against *P.* 197 vivax and other zoonotic Plasmodium species (25).

198 Limit of detection evaluation for PCR assays with and without RT

199 The initial microscopy-quantified Plasmodium species infected samples collected in 200 DNA/RNA ShieldTM were diluted with malaria-negative whole blood (also at the same manufacturer recommended DNA/RNA ShieldTM ratio) to prepare individual parasite count 201 202 dilutions ranging between 20 to 0.0002 parasites/µL. Total nucleic acids from samples at each 203 serial parasite count dilution were then extracted and duplicate aliquots prepared. Highcapacity cDNA reverse transcription (Applied BiosystemsTM, Thermo Fisher Scientific, MA, 204 205 USA) was then performed on one aliquot from each pair. PCR was performed on the paired 206 aliquots to detect P. genus by the qPCR assay (26), followed by species-specific assays for: P. 207 knowlesi by the reference hemi-nested assay (24) and test assays A, B, C (25,27,29); P. vivax 208 (23) and P. cynomolgi (25) by reference assays, in addition to the newly designed P. vivax 209 primers. The LOD was expressed as the lowest parasite count per microlitre of whole blood 210 detected by an individual PCR assay in both amplification replicates (Figure 1C).

211 Limit of detection of *P*. genus qPCR assay for dried blood spots (DBS) with and without 212 RT

The LOD for the *P*. genus qPCR assay was also evaluated using archived DBS from *P. knowlesi* clinical infections with and without RT (**Figure 1C**). DBS were stored individually after collection with dessicant at room temperature unexposed to light before processing. Nucleic acids were extracted from the DBS samples, with 10µl immediately reverse transcribed into cDNA. *P.* genus qPCR was conducted on serial 1:10 DNA and cDNA dilutions with the LOD calculated using the initial enumerated parasitemia divided by the corresponding dilution level.

219 Evaluation of PCR assay specificity on clinical malaria samples

For the analysis of *P. knowlesi*, *P. falciparum*, and *P. vivax* clinical isolates, in addition to a *P. cynomolgi* macaque-derived isolate, all samples were individually tested using the *P.* genus

qPCR assay and the three *P. knowlesi*-specific PCR assays. Results were compared against the reference PCR. Specificity for the *P.* genus assay was evaluated for malaria detection (any *Plasmodium* species) versus malaria-negative controls, and for species-specific assays using the corresponding *Plasmodium* species infection versus other *Plasmodium* species and malarianegative controls combined. Clinical blood samples collected in EDTA likely had RNA degradation upon thawing; therefore, reverse transcription was not performed for this part of the analysis.

229 Statistical analyses

230 Parasite counts for each clinical *Plasmodium* species infection were summarised using median 231 and interquartile range (IQR). The median whole blood LOD was calculated with and without 232 reverse transcription for the P. knowlesi and P. vivax isolates. To calculate the LOD fold-233 change, the LOD without RT was divided by the LOD with RT. One-way ANOVA was used 234 to test for differences in parasite count distribution across *Plasmodium* species, followed by 235 Student's t-test for pairwise comparisons of log-transformed data. Results of PCR assays 236 evaluated against reference PCR were defined as true positive (TP), false negative (FN), true negative (TN), and false positive (FP), enabling calculation of diagnostic sensitivity 237 238 (TP/TP+FN) and specificity (TN/TN+FP) with exact binomial 95% confidence intervals. All statistical analyses were performed using Stata version 17.0 (StataCorp, Texas, USA). 239

240

241 **RESULTS**

242 Limit of detection of *P*. genus PCR assays

The LOD was performed on *P. knowlesi* (n=4), *P. vivax* (n=4) and *P. cynomolgi* (n=1) whole blood isolates. For the *P.* genus Kamau et al. qPCR assay, without reverse transcription, the median LOD to detect each individual *Plasmodium* species was 2 parasites/ μ L (**Table 2** and

246	Figure 2A). With reverse transcription, the assay sensitivity for <i>P. knowlesi</i> improved with a
247	LOD of ≤ 0.0002 parasites/µL for all four isolates (10,000-fold change). The LOD for both <i>P</i> .
248	vivax and P. cynomolgi improved to 0.002 parasites/µL with RT (1,000-fold change); Figure
249	2B . In comparison, the reference Snounu <i>P</i> . genus assay had a slightly higher LOD for <i>P</i> . <i>vivax</i>
250	and <i>P. cynomolgi</i> without RT (0.2 parasites/µL for both); however, with RT a less pronounced
251	improvement in LOD was demonstrated at 0.02 and 0.01 parasites/ μ L, respectively.
252	

Table 2. Limit of detection (LOD) of *Plasmodium* genus and species-specific PCR assays 253

254

PCR assay	Target <i>P</i> .	Tested species	LOD without RT	LOD with RT	Fold change post RT (x)
	genus/species	•			
Kamau et al. (26)	P. genus	Pk	2	≤0.0002	10000
Kamau et al. (26)	P. genus	Pv	2	0.002	1000
Kamau et al. (26)	P. genus	Pc	2	0.002	1000
Snounou et al. (23)	P. genus	Pk	2	0.0011	1818
Snounou et al. (23)	P. genus	Pv	0.2	0.02	10
Snounou et al. (23)	P. genus	Pc	0.2	0.01	20
Imwong et al. (24)	Pk	Pk	2	0.0007	2759
Divis et al. (27)	Pk	Pk	0.2	≤0.0002	1000
Lee et al. (25)	Pk	Pk	11	11	No change
Lubis et al. (29)	Pk	Pk	0.11	1.1	0.1*
Snounou et al. (23)	Pv	Pv	20	0.02	1000
Snounou et al. (23)	Pv	[#] Pc	0.2	0.02	10
Lee et al. (25)	Pc	Pc	2	0.2	10

255 256 257 258 Abbreviations: P. genus = Plasmodium genus; Pk = P. knowlesi; Pv = P. vivax; Pc = P. cynomolgi; RT = reverse transcription

LOD is the lowest parasitemia (parasites/µL) detected by all three replicates for each PCR assay

259 LOD and fold-change post RT are reported as median for P. knowlesi (n=4)

260 *There was no improvement in LOD by Lubis PCR assay (Test B) after RT

261 [#]P. vivax assay cross-reacts with P. cynomolgi

262

263 Limit of detection of *Plasmodium* species-specific PCR assays

For the *P. knowlesi*-specific assays, the median LOD without and with reverse transcription was 2 and 0.0007 parasites/ μ L, respectively, for the Imwong et al. reference assay (2759-fold change); 0.2 and 0.0002 parasites/ μ L, respectively, for Test A (1000-fold); 0.11 and 1.1 parasites/ μ L, respectively, for Test B (no improvement); and 11 parasites/ μ L for both (no

268 change) for Test C (**Table 2 and Figure 2A**).

269 Without reverse transcription, the LODs using species-specific reference assays were 2

270 parasites/µL for *P. cynomolgi* and 20 parasites/µL for *P. vivax*. With reverse transcription, the

271 LODs were 0.2 (10-fold change) and 0.02 (1000-fold change) for *P. cynomolgi* and *P. vivax*

272 respectively. However, additional testing of the *P. cynomolgi* isolate using the reference *P*.

273 vivax-targeted rVIV1/rVIV2 primers (23) amplified this target from the macaque-origin P.

274 *cynomolgi* infection both without (0.2 parasites/ μ L) and with reverse transcription (0.02

275 parasites/µL), producing a false-positive *P. vivax* result (**Table 2 and Figure 2B**).

The LOD with reverse transcription of the *P*. genus assay was comparable to the LOD of the

277 best performing species-specific assay for P. knowlesi detection (≤0.0002 parasites/µL for

both). In contrast, the *P*. genus assay had a superior LOD compared to the reference species-

specific assays for *P. vivax* (0.002 vs 0.02 parasites/µL respectively) and *P. cynomolgi* (0.002
vs 0.2 parasites/µL respectively).

281 Limit of detection of *P*. genus qPCR for dried blood spots (DBS)

282 The median LOD between DNA and cDNA generated from dried blood spots (DBS) for 4 *P*.

283 knowlesi extracted samples collected 8 months prior to evaluation of the P. genus Kamau 2011

assay without and with RT was 19.86 and 0.08 parasites/uL, respectively (249-fold change);

Table 3. Archived DBS samples (n=12) collected more than 6 years (up to 11 years) prior to

extraction demonstrated a similar LOD with and without RT (median 20 parasites/ μ L).

287

Table 3. Limit of detection of the 18S rRNA *P*. genus qPCR assay for *P. knowlesi* dried blood spot samples

290

Species evaluated	Initial parasitemia (/µL)	Time from DBS collection	LOD without RT (DNA)	LOD with RT (cDNA)	Fold change post RT (x)
Recent sam	ples				
Pk	2663	8 months	26.6	0.027	1000
Pk	1377	8 months	13.8	0.138	100
Pk	198	8 months	2.0	0.020	100
Pk	26	8 months	26.0	2.600	10
Median	788	8 months	19.9	0.08	100
(IQR)	(198-1377)		(13.8-26.0)	(0.03-0.14)	(100-100)
Archived s	amples [†]				
Pk	372	11 years	20	20	1
(N=12)	(177-2604)	(8-11)*	(2.5-20)	(2-20)	(1-1.25)

²⁹¹

292 Limit of detection (parasites/ μ L) with and without RT of each *P. knowlesi* isolate was conducted in duplicate for 293 each target species at each dilution level.

[†]Results are median (IQR)

295 *Range from 6 to 11 years

296 Pk = P. knowlesi

- 297
- 298
- 299

300 Specificity of *P*. genus and individual *Plasmodium* species PCR assays

301 A total of 239 samples were included in the clinical evaluation of test specificity without RT,

302 consisting of 96 P. knowlesi, 50 P. vivax, 44 P. falciparum, and 1 P. cynomolgi infected

303 samples, and 48 malaria-negative controls. The median parasitemia was 1,957/µL (IQR 261-

304 5,762; range 27-210,100 parasites/µL) for *P. knowlesi*, 3,246/µL (IQR 1,588-7,306; range 77-

305 20,064 parasites/µL) for *P. vivax*, and 14,015/µL (IQR 2,193-33,413; range 34-297,000

306 parasites/ μ L) for *P. falciparum*.

307 The *P*. genus qPCR screening assay was both 100% specific and sensitive for the detection of

308 Plasmodium species overall compared to the reference PCR, with all 48 samples from

309 uninfected controls confirmed as malaria-negative.

P. knowlesi- assays for Tests A (27) and B (29) correctly identified all 96 *P. knowlesi* and 95
non-*P. knowlesi* samples, resulting in 100% specificity and sensitivity. Test C (25) was
negative for a single *P. knowlesi* isolate with a parasite count of 1,535 parasites/µL, resulting
in 99% (95% CI 94.3-100.0) sensitivity and 100% specificity. The reference assays for *P. falciparum* and *P. vivax* (23), and for *P. cynomolgi* (25) were negative for all *P. knowlesi*clinical isolates tested (**Table 2**).

316

317

318 **DISCUSSION**

319

320 Malaria-susceptible countries in most of Southeast Asia, including those approaching or 321 achieving WHO elimination of major human-only Plasmodium species, remain at-risk for 322 zoonotic malaria transmission (30,31). Understanding regional heterogeneity in P. knowlesi 323 transmission intensity and disease morbidity will require the selective deployment of highly 324 sensitive and specific molecular detection tools for both diagnostic and surveillance purposes 325 (19). Our major finding demonstrated that the use of a reverse-transcription step after extraction 326 of preserved total nucleic acids in clinical samples considerably improves the limit of detection 327 of both the selected P. genus RT-qPCR screening assay, and P. knowlesi-specific assays 328 (reference and Test A; both >1000-fold) by additionally amplifying ribosomal RNA sequences. 329 The enhanced limit of detection was consistent across both field-stable DNA/RNA ShieldTM 330 samples and to a lesser degree in recent (although not older) dried blood spots. The second key 331 finding of this study was the excellent performance of the *P*. genus screening assay, originally 332 developed and validated for use in an African context for P. falciparum (26), to detect previously unvalidated species including P. knowlesi, P. cynomolgi and P. vivax. The 333 334 specificity of each of the *P. knowlesi*-targeted assays to exclude *P. cynomolgi* and non-zoonotic *Plasmodium* species was confirmed to be excellent. Together these findings highlight the potential utility of incorporating these assays in a molecular surveillance approach to detect both human and zoonotic *Plasmodium* species that are well below the reported parasite count detection limits for current conventional PCR, loop-mediated isothermal amplification, microscopy or parasite lactate-dehydrogenase-based rapid diagnostic tests (19).

340

341 The community-based detection of submicroscopic P. knowlesi and P. cynomolgi infections, 342 both symptomatic or asymptomatic, requires ultrasensitive molecular tools to understand the 343 true extent of population-level transmission (19). Recent studies in areas of both Peninsular 344 Malaysia and the East Malaysian state of Sarawak have reported human infections in local 345 communities living in or near forested areas with other macaque malaria species, including P. 346 inui, P. coatneyi, P. fieldi and possibly P. simiovale, in addition to P. knowlesi and P. cynomolgi 347 (32). It is unclear whether or to what extent these low-level zoonotic infections may facilitate 348 onward transmission to humans (33,34), as occurs with low parasitemia *P. falciparum* and *P.* 349 vivax infections (35.36), although sustained human-to-human transmission of P. knowlesi has 350 not been evident to date(25,37).

351

The selection of the major RT-qPCR P. genus screening assay aimed to maximise the detection 352 353 limits for low-level zoonotic *Plasmodium* species infections due to the known high multicopy 354 number (5 to 10 copies per genome depending on the Plasmodium species) of the 18S rRNA 355 target (38), in addition to amplification of both the A- and S- type genes and their RNA 356 transcripts (26). The excellent LOD demonstrated with the P. genus RT-qPCR assay in the 357 current study of <0.0002 parasites/µL for *P. knowlesi* detection is consistent with a previously reported extremely low LOD of ~0.0004 parasites/µL for clinical *P. falciparum* samples (26). 358 359 DNA-concentrated packed red blood cell samples have been demonstrated to further improve

360 sensitivity for P. falciparum detection in population-based malaria prevalence surveys in 361 elimination areas of Thailand (39). Comparable performance to this P. genus RT-qPCR assay 362 was reported with a separately established ultrasensitive quantitative PCR method (uPCR) with 363 a limit of detection of 0.022 parasites/µL (39), however, a major advantage of the reverse 364 transcriptase qPCR assay is the requirement for comparatively lower blood volumes (18). 365 Interestingly, in the current study the conventional PCR P. genus reference assay also 366 demonstrated a large increase in analytical sensitivity after reverse transcription (~1800-fold) 367 and may provide a more cost-effective option compared to qPCR for surveillance purposes. DNA/RNA ShieldTM was selected as the preferred blood collection preservation method over 368 369 other media due to its reported ability to stabilise DNA/RNA at ambient temperatures in field 370 settings and compatibility with most DNA and RNA purification kits for subsequent high-371 throughput workflows including reverse transcription (40).

372

373 To date, only a few studies have incorporated reverse transcription in the molecular detection 374 of *Plasmodium* species (41.42). The reverse transcription step in the present study improved 375 the analytical sensitivity of our selected assays to detect zoonotic P. knowlesi, P. cynomolgi 376 and other human malaria infections by up to 10,000-fold (Plasmodium genus), 2759-fold (P. 377 knowlesi), 1000-fold (P. vivax) and 10-fold (P. cynomolgi), respectively. The P. knowlesi-378 specific hemi-nested reference assay with reverse transcription demonstrated a comparable 379 limit of detection to the qPCR Test A (which requires an expensive real-time hydrolysis probe), 380 and was superior to both Test B targeting *SICavar* and Test C targeting the 18S rRNA gene. 381 Without reverse transcription, the lowest limit of detection for *P. knowlesi* was seen with Test 382 B, suggesting that the multiple chromosomal copies of the variant antigen SICAvar provide 383 equivalent or better signal amplification than the detection of transcripts from whichever of 384 these gene copies is activated in any particular parasite cell in the peripheral blood. Constraints

385 on the widespread use of reverse transcription include the additional cost, laboratory time, and 386 the usual rapid degradation of RNA molecules in field or laboratory settings. However, the 387 degree of RNA amplification with reverse transcription was aided in our study by collecting 388 blood samples in room-temperature stable RNA preservation media suitable for field-based 389 surveillance, which also allows other potential downstream pathophysiological or 390 transcriptomic analyses dependent on pathogen or host RNA transcripts.

391

392 The low reported limit of detection for the RT-qPCR *P*. genus assay conducted on DBS in this 393 study (~0.08 parasites/µL with reverse transcription) suggests this type of sample collection 394 would also enable the identification of a large proportion of submicroscopic and/or 395 asymptomatic infections. DBS collection is logistically a more feasible, inexpensive and 396 acceptable option particularly for asymptomatic or younger participants (given the need for 397 fingerprick blood collection rather than venepuncture) for large-scale malaria surveillance 398 surveys. However, the reverse transcription step only improved the LOD in DBS samples that 399 were collected within 8 months; older DBS stored in recommended conditions for more than 6 400 years did not provide any improvement in the LOD with and without RT due to likely 401 degradation of RNA. Regardless, the P. genus LOD of around 2 to 20 parasites/µL without RT 402 for DBS samples remains encouraging as a first-line option for surveillance screening purposes, 403 although the use of DBS would require further evaluation with *Plasmodium* species-specific 404 PCR assay differentiation.

405

The current study confirmed previous findings detailing cross-reactivity between the nested PCR primers for *P. vivax* (rVIV1/rVIV2) with *P. cynomolgi* (13). A single mismatch in the 30 nucleotides of the rVIV2 primer sequences was reported to cross-amplify *P. cynomolgi* isolates (13). The nested *P. vivax*-specific assay using the same primers rVIV1/rVIV2 designed to

410 target the 18S rRNA gene also amplified *P. cynomolgi* in our LOD analysis (23). The separate 411 P. cynomolgi primers remained highly specific and did not erroneously amplify P. vivax or 412 other closely related *Plasmodium* species DNA. In practice, the concurrent use of both assays 413 would enable accurate identification of a *P. vivax* mono-infection, however, this approach 414 would not be able to differentiate a P. vivax/P. cynomolgi co-infection from a P. cynomolgi 415 mono-infection. Mis-identification of symptomatic P. cynomolgi infections as P. vivax would 416 not result in inappropriate treatment, given both have a latent hypnozoite liver life-stage 417 requiring additional radical cure with primaguine. Most other commonly used single-round 418 multiplex (43) and qPCR assays (44) containing *P. vivax*-specific targets have also not been 419 validated against isolates of P. cynomolgi or other closely related macaque Plasmodium 420 species. However, a variety of sequencing approaches of targeted gene amplicons including 421 mitochondrial COX1 and cytochrome b, SICAvar and SSU 18S rRNA followed by sequencing 422 and reference alignment have been used to confirm unknown or mixed zoonotic Plasmodium 423 species infections following initial ambiguous PCR results (45,46).

424

425 A limitation of this study was the inability to validate submicroscopic clinical P. knowlesi 426 infections and other zoonotic species such as *P. fieldi*, *P. inui* and *P. coatnevi* for which samples 427 were not available. Due to the increasing number of published P. knowlesi assays, we were not 428 able to evaluate other P. knowlesi assays of possibly comparable performance within our 429 selected workflow. We were also unable to evaluate mixed infections of P. knowlesi, P. vivax 430 and *P. falciparum* despite these cases being reported in certain areas such as Indonesia (29) 431 and Vietnam (47). Due to sample availability, we were also restricted to only a single P. 432 cynomolgi sample to determine the LOD of the P. cynomolgi-specific assay (25). The discrepancy between the LOD for the P. genus qPCR screening assay and the species-specific 433

434 assay for *P. cynomolgi* detection may mean a proportion of very low-level *P. cynomolgi*435 infections are unable to be identified beyond a *P.* genus threshold using the current protocol.

436

437 CONCLUSIONS

The *Plasmodium* genus reverse transcriptase qPCR assay can provide highly sensitive 438 439 screening for zoonotic and human malaria, including for submicroscopic infections in at-risk 440 populations in endemic areas. The use of this molecular surveillance protocol for either whole 441 blood or DBS collected samples in understudied areas of Southeast Asia would enable 442 improved understanding of the regional disease burden and transmission dynamics of zoonotic 443 malaria. Enhanced molecular tools and future iterative improvements to conventional 444 surveillance protocols are especially critical as Southeast Asia continues to exert considerable 445 public health efforts towards human malaria elimination despite the challenge of additional zoonotic *Plasmodium* species infections at an expanding human-animal-interface. 446

447

448 **DECLARATIONS**

449 Ethics approval and consent to participate

Sample collection and diagnostic evaluation were approved as part of prospective malaria studies by the Medical Research and Ethics Committee (MREC), Ministry of Health Malaysia (NMRR-10-754-6684, NMRR-19-4109-52172 and NMRR-19-3229-49967), Universitas Sumatera Utara, Indonesia (#723/KEP/USU/2021) and by the Menzies School of Health Research, Australia (HREC-2010-1431 and HREC-2022-4417) in accordance with all applicable Federal and other regulations governing the protection of human subject research.

456 **Competing interests**

457 The authors declare that they have no competing interests.

458 Funding

459 This work was supported by the ZOOMAL project, funded through the Australian Centre for 460 International Agricultural Research and Indo-Pacific Centre for Health Security, DFAT, 461 Australian Government (#LS-2019-116), the National Institutes of Health, USA 462 (#R01AI160457-01), and DOD-DHA-Global Emerging Infections Surveillance program project P0097 22 N2.). Funding support was also through the National Health and Medical 463 464 Research Council, Australia (Grant Numbers #1037304 and #1045156, fellowship to NMA [#1042072], Emerging Leadership 2 Investigator Grants to MJG [#2017436] and BEB 465 466 [#2016792]), and the Ministry of Health, Malaysia (#BP00500/117/1002) awarded to GSR.

467 **Disclaimers**

468 The views expressed are those of the author(s) and do not necessarily reflect the official policy 469 or position of the Department of the Navy, Department of Defense, nor the U.S. Government. 470 Copyright Statement: NC (LCDR, MSC, USN) & AL (CAPT, MC, USN) are military service 471 members and employees of the U.S. Government. This work was prepared as part of their 472 official duties at U.S. Naval Medical Research Unit INDO PACIFIC. Title 17 U.S.C. §105 473 provides that 'Copyright protection under this title is not available for any work of the United 474 States Government.' Title 17 U.S.C. §101 defines a U.S. Government work as a work prepared 475 by a military service member or employee of the U.S. Government as part of that person's 476 official duties.

477 Authors' contributions

478	Conceptualization, funding acquisition, methodology and resources: MG, NA, KB, KP, INL,
479	RN, CP, NC, AL. Sample processing and conduct of assays: KP and PK. Data analyses: KB,
480	MG, KP. Initial manuscript preparation and writing: KB, MG. All authors read and approved
481	the final manuscript.
482	Acknowledgements
483	We thank the study participants, the IDSKKS malaria research team (Mohd Rizan Osman,
484	Danshy Alaza, Azielia Elastiqah, Sitti Saimah binti Sakam), and Bruce Russell of the
485	Department of Microbiology & Immunology, University of Otago, Dunedin, New Zealand, for
486	providing the P. cynomolgi isolate. We thank the Director General of Health Malaysia for the
487	permission to publish this article.
488	
489	
490	
491	REFERENCES
492	
493	1. Moyes CL, Henry AJ, Golding N, Huang Z, Singh B, Baird JK, et al. Defining the
494	Geographical Range of the Plasmodium knowlesi Reservoir. PLoS Neglected Trop Dis.
495	2014;8(3):e2780.
496	2. Cuenca PR, Key S, Jumail A, Surendra H, Ferguson HM, Drakeley C, et al. Epidemiology
497	of the zoonotic malaria Plasmodium knowlesi in changing landscapes. Adv Parasit.
498	2021;113:225-86.
499	3. Barber BE, William T, Grigg MJ, Menon J, Auburn S, Marfurt J, et al. A Prospective
500	Comparative Study of Knowlesi, Falciparum, and Vivax Malaria in Sabah, Malaysia: High

- 501 Proportion With Severe Disease From *Plasmodium knowlesi* and *Plasmodium vivax* But No
- Mortality With Early Referral and Artesunate Therapy. Clin Infect Dis. 2013 Feb;56(3):383–
 97.
- 504 4. Daneshvar C, Davis TME, Cox-Singh J, Rafa'ee MZ, Zakaria SK, Divis PCS, et al.
- 505 Clinical and laboratory features of human *Plasmodium knowlesi* infection. Clinical Infectious
- 506 Diseases [Internet]. 2009 Sep 15;49(6):852–60. Available from:
- 507 <u>http://cid.oxfordjournals.org/lookup/doi/10.1086/605439</u>
- 508 5. Grigg MJ, William T, Barber BE, Rajahram GS, Menon J, Schimann E, et al. Age-Related
- 509 Clinical Spectrum of *Plasmodium knowlesi* Malaria and Predictors of Severity. Clin Infect
- 510 Dis. 2018 Aug 1;67(3):350–9.
- 511 6. Kotepui M, Masangkay FR, Kotepui KU, Milanez GDJ. Preliminary review on the
- 512 prevalence, proportion, geographical distribution, and characteristics of naturally acquired
- 513 Plasmodium cynomolgi infection in mosquitoes, macaques, and humans: a systematic review
- and meta-analysis. BMC Infect Dis. 2021;21(1):259.
- 515 7. Grigg MJ, Lubis IN, Tetteh KKA, Barber BE, William T, Rajahram GS, et al. *Plasmodium*
- 516 knowlesi detection methods for human infections—Diagnosis and surveillance. In: Advances
- 517 in Parasitology [Internet]. Academic Press; 2021. p. 77–130. (Drakeley C, editor. Advances
- 518 in Parasitology; vol. 113). Available from:
- 519 <u>https://www.sciencedirect.com/science/article/pii/S0065308X21000270</u>
- 520 8. WHO. Malaria Policy Advisory Group (MPAG) meeting (March 2022) [Internet]. 2022
- 521 Apr. Available from: <u>https://www.who.int/publications/i/item/9789240048430</u>

522	9.	Barber BE.	William T.	Grigg MJ.	Yeo TW.	Anstev	v NM.	Limitations	of m	icroscopy	to
			,		,	,	/				

- 523 differentiate *Plasmodium* species in a region co-endemic for *Plasmodium falciparum*,
- 524 *Plasmodium vivax* and *Plasmodium knowlesi*. Malaria J. 2013 Jan 8;12(1):8.
- 525 10. Lee KS, Cox-Singh J, Singh B. Morphological features and differential counts of
- 526 Plasmodium knowlesi parasites in naturally acquired human infections. Malaria J. 2009 Apr
- 527 23;8(1):73–73.
- 528 11. Coutrier FN, Tirta YK, Cotter C, Zarlinda I, González IJ, Schwartz A, et al. Laboratory
- 529 challenges of *Plasmodium* species identification in Aceh Province, Indonesia, a malaria
- 530 elimination setting with newly discovered *P. knowlesi*. PLoS Neglected Trop Dis [Internet].
- 531 2018;12(11):e0006924. Available from: <u>https://doi.org/10.1371/journal.pntd.0006924</u>
- 532 12. Hartmeyer GN, Stensvold CR, Fabricius T, Marmolin ES, Hoegh SV, Nielsen HV, et al.
- 533 *Plasmodium cynomolgi* as Cause of Malaria in Tourist to Southeast Asia, 2018. Emerging
- 534 infectious diseases. 2019 Oct;25(10):1936–9.
- 535 13. Ta TH, Hisam S, Lanza M, Jiram AI, Ismail N, Rubio JM. First case of a naturally
- 536 acquired human infection with *Plasmodium cynomolgi*. Malaria J. 2014;13(1):68.
- 537 14. Barber BE, William T, Grigg MJ, Piera K, Yeo TW, Anstey NM. Evaluation of the
- 538 Sensitivity of a pLDH-Based and an Aldolase-Based Rapid Diagnostic Test for Diagnosis of
- 539 Uncomplicated and Severe Malaria Caused by PCR-Confirmed Plasmodium knowlesi,
- 540 Plasmodium falciparum, and Plasmodium vivax. J Clin Microbiol. 2013 Apr 1;51(4):1118–

541 23.

- 542 15. Grigg MJ, William T, Barber BE, Parameswaran U, Bird E, Piera K, et al. Combining
- 543 Parasite Lactate Dehydrogenase-Based and Histidine-Rich Protein 2-Based Rapid Tests To

- 544 Improve Specificity for Diagnosis of Malaria Due to *Plasmodium knowlesi* and Other
- 545 *Plasmodium* Species in Sabah, Malaysia. J Clin Microbiol. 2014 Apr;52(6):2053–60.
- 546 16. Tan AF, Sakam SS binti, Rajahram GS, William T, Isnadi MFAR, Daim S, et al.
- 547 Diagnostic accuracy and limit of detection of ten malaria parasite lactate dehydrogenase-
- 548 based rapid tests for *Plasmodium knowlesi* and *P. falciparum*. Front Cell Infect Microbiol
- 549 [Internet]. 2022;12:1023219. Available from:
- 550 https://www.frontiersin.org/articles/10.3389/fcimb.2022.1023219
- 551 17. Lee PC, Chong ETJ, Anderios F, Lim YA, Chew CH, Chua KH. Molecular detection of
- 552 human *Plasmodium* species in Sabah using PlasmoNexTM multiplex PCR and hydrolysis
- probes real-time PCR. Malaria Journal. 2015 Jan 28;14(1):28.
- 18. Christensen P, Bozdech Z, Watthanaworawit W, Renia L, Malleret B, Ling C, et al.
- 555 Reverse transcription PCR to detect low density malaria infections. Wellcome Open Res.

556 2021;6:39.

- 557 19. Anstey NM, Grigg MJ. Zoonotic Malaria: The Better You Look, the More You Find. J
- 558 Infect Dis [Internet]. 2019;219(5):679–81. Available from:
- 559 <u>https://www.ncbi.nlm.nih.gov/pubmed/30295775</u>
- 560 20. Christensen P, Racklyeft A, Ward KE, Matheson J, Suwanarusk R, Chua ACY, et al.
- 561 Improving in vitro continuous cultivation of *Plasmodium cynomolgi*, a model for *P. vivax*.
- 562 Parasitol Int. 2022;89:102589.
- 563 21. WHO. Microscopy for the detection, identification and quantification of malaria parasites
- on stained thick and thin blood films in research settings. World Health Organisation
- 565 [Internet]. 2015; Available from: <u>https://apps.who.int/iris/handle/10665/163782</u>

- 566 22. Zainabadi K, Adams M, Han ZY, Lwin HW, Han KT, Ouattara A, et al. A novel method
- 567 for extracting nucleic acids from dried blood spots for ultrasensitive detection of low-density
- 568 *Plasmodium falciparum* and *Plasmodium vivax* infections. Malar J [Internet].
- 569 2017;16(1):377. Available from: <u>https://doi.org/10.1186/s12936-017-2025-3</u>
- 570 23. Snounou G, Viriyakosol S, Jarra W, Thaithong S, Brown KN. Identification of the four
- 571 human malaria parasite species in field samples by the polymerase chain reaction and
- 572 detection of a high prevalence of mixed infections. Molecular and biochemical parasitology.
- 573 1993 Apr;58(2):283–92.
- 574 24. Imwong M, Tanomsing N, Pukrittayakamee S, Day NPJ, White NJ, Snounou G. Spurious
- 575 Amplification of a *Plasmodium vivax* Small-Subunit RNA Gene by Use of Primers Currently
- 576 Used To Detect *P. knowlesi*. J Clin Microbiol [Internet]. 2009;47(12):4173–5. Available
- 577 from: <u>https://www.ncbi.nlm.nih.gov/pubmed/19812279</u>
- 578 25. Lee KS, Divis PCS, Zakaria SK, Matusop A, Julin RA, Conway DJ, et al. Plasmodium
- 579 *knowlesi*: Reservoir Hosts and Tracking the Emergence in Humans and Macaques. Kazura
- 580 JW, editor. PLoS Pathog. 2011;7(4):e1002015.
- 581 26. Kamau E, Tolbert LS, Kortepeter L, Pratt M, Nyakoe N, Muringo L, et al. Development
- 582 of a Highly Sensitive Genus-Specific Quantitative Reverse Transcriptase Real-Time PCR
- 583 Assay for Detection and Quantitation of *Plasmodium* by Amplifying RNA and DNA of the
- 584 18S rRNA Genes. J Clin Microbiol [Internet]. 2011;49(8):2946–53. Available from:
- 585 <u>https://www.ncbi.nlm.nih.gov/pubmed/21653767</u>
- 586 27. Divis PC, Shokoples SE, Singh B, Yanow SK. A TaqMan real-time PCR assay for the
- 587 detection and quantitation of *Plasmodium knowlesi*. Malar J [Internet]. 2010;9(1):344.
- 588 Available from: <u>https://www.ncbi.nlm.nih.gov/pubmed/21114872</u>

- 589 28. Nuin NA, Tan AF, Lew YL, Piera KA, William T, Rajahram GS, et al. Comparative
- 590 evaluation of two commercial real-time PCR kits (QuantiFastTM and abTESTM) for the
- 591 detection of *Plasmodium knowlesi* and other *Plasmodium* species in Sabah, Malaysia.
- 592 Malaria J. 2020 Aug;19(1):306.
- 593 29. Lubis IND, Wijaya H, Lubis M, Lubis CP, Divis PCS, Beshir KB, et al. Contribution of
- 594 Plasmodium knowlesi to Multispecies Human Malaria Infections in North Sumatera,
- 595 Indonesia. J Infect Dis [Internet]. 2017;215(7):1148–55. Available from:
- 596 https://www.ncbi.nlm.nih.gov/pubmed/28201638
- 597 30. Shearer FM, Huang Z, Weiss DJ, Wiebe A, Gibson HS, Battle KE, et al. Estimating
- 598 Geographical Variation in the Risk of Zoonotic *Plasmodium knowlesi* Infection in Countries
- 599 Eliminating Malaria. Churcher TS, editor. PLoS Neglected Trop Dis [Internet].
- 600 2016;10(8):e0004915. Available from: <u>https://doi.org/10.1371/journal.pntd.0004915</u>
- 601 31. Tobin RJ, Harrison LE, Tully MK, Lubis IND, Noviyanti R, Anstey NM, et al. Updating
- 602 estimates of *Plasmodium knowlesi* malaria risk in response to changing land use patterns
- across Southeast Asia. PLOS Neglected Trop Dis. 2024;18(1):e0011570.
- 604 32. Yap NJ, Hossain H, Nada-Raja T, Ngui R, Muslim A, Hoh BP, et al. Natural Human
- 605 Infections with *Plasmodium cynomolgi*, *P. inui*, and 4 other Simian Malaria Parasites,
- 606 Malaysia Volume 27, Number 8—August 2021 Emerging Infectious Diseases journal -
- 607 CDC. Emerg Infect Dis [Internet]. 2021;27(8):2187–91. Available from:
- 608 <u>https://www.ncbi.nlm.nih.gov/pubmed/34287122</u>
- 609 33. Fornace KM, Nuin NA, Betson M, Grigg MJ, William T, Anstey NM, et al.
- 610 Asymptomatic and Submicroscopic Carriage of *Plasmodium knowlesi* Malaria in Household

and Community Members of Clinical Cases in Sabah, Malaysia. J Infect Dis. 2016 Mar
1;213(5):784–7.

- 613 34. Noordin NR, Lee PY, Bukhari FDM, Fong MY, Hamid MHA, Jelip J, et al. Prevalence of
- 614 Asymptomatic and/or Low-Density Malaria Infection among High-Risk Groups in Peninsular
- 615 Malaysia. Am J Trop Med Hyg. 2020;103(3):1107–10.
- 616 35. Schneider P, Bousema JT, Gouagna LC, Otieno S, Vegte-Bolmer MV de, Omar SA, et al.
- 617 Submicroscopic *Plasmodium falciparum* gametocyte densities frequently result in mosquito
- 618 infection. American Journal of Tropical Medicine and Hygiene. 2007;76(3):470–4.
- 619 36. Almeida ACG, Kuehn A, Castro AJM, Vitor-Silva S, Figueiredo EFG, Brasil LW, et al.
- 620 High proportions of asymptomatic and submicroscopic *Plasmodium vivax* infections in a
- 621 peri-urban area of low transmission in the Brazilian Amazon. Parasites Vectors.
- 622 2018;11(1):194.
- 623 37. Fornace KM, Topazian HM, Routledge I, Asyraf S, Jelip J, Lindblade KA, et al. No
- 624 evidence of sustained nonzoonotic *Plasmodium knowlesi* transmission in Malaysia from
- 625 modelling malaria case data. Nat Commun. 2023;14(1):2945.
- 626 38. Mercereau-Puijalon O, Barale JC, Bischoff E. Three multigene families in *Plasmodium*
- 627 parasites: facts and questions. Int J Parasitol [Internet]. 2002;32(11):1323–44. Available
- 628 from: https://www.sciencedirect.com/science/article/pii/S002075190200111X
- 629 39. Imwong M, Hanchana S, Malleret B, Renia L, Day NPJ, Dondorp A, et al. High-
- 630 throughput ultrasensitive molecular techniques for quantifying low-density malaria
- 631 parasitemias. Gilligan PH, editor. Journal of clinical microbiology [Internet]. 2014

632 Sep;52(9):3303–9. Available from:

- 633 <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313154/pdf/zjm3303.pdf</u>
- 634 40. Eberhardt E, Hendrickx R, Kerkhof MV den, Monnerat S, Alves F, Hendrickx S, et al.
- 635 Comparative evaluation of nucleic acid stabilizing reagents for RNA- and DNA-based
- 636 Leishmania detection in blood as proxy for visceral burdens. J Microbiol Methods.

637 2020;173:105935.

- 638 41. Adams M, Joshi SN, Mbambo G, Mu AZ, Roemmich SM, Shrestha B, et al. An
- 639 ultrasensitive reverse transcription polymerase chain reaction assay to detect asymptomatic
- 640 low-density *Plasmodium falciparum* and *Plasmodium vivax* infections in small volume blood
- 641 samples. Malar J. 2015 Dec 23;14(1):520.
- 642 42. Bousema T, Banman SL, Taylor BJ, Rijpma SR, Morlais I, Yanow SK, et al. A Direct
- 643 from Blood Reverse Transcriptase Polymerase Chain Reaction Assay for Monitoring
- 644 Falciparum Malaria Parasite Transmission in Elimination Settings. Am J Trop Med Hyg.

645 2017;97(2):533–43.

- 646 43. Padley D, Moody AH, Chiodini PL, Saldanha J. Use of a rapid, single-round, multiplex
- 647 PCR to detect malarial parasites and identify the species present. Ann Trop Med Parasitol
- 648 [Internet]. 2003;97(2):131–7. Available from: <u>https://doi.org/10.1179/000349803125002977</u>
- 649 44. Rougemont M, Saanen MV, Sahli R, Hinrikson HP, Bille J, Jaton K. Detection of Four
- 650 Plasmodium Species in Blood from Humans by 18S rRNA Gene Subunit-Based and Species-
- 651 Specific Real-Time PCR Assays. J Clin Microbiol [Internet]. 2004;42(12):5636–43.
- 652 Available from: https://journals.asm.org/doi/abs/10.1128/JCM.42.12.5636-5643.2004

	653	45. Imwong M, Madmane	e W	, Suwannasin K	, Kunasol C.	, Peto TJ	, Tripura R	, et al.
--	-----	-----------------------	-----	----------------	--------------	-----------	-------------	----------

- 654 Asymptomatic Natural Human Infections With the Simian Malaria Parasites *Plasmodium*
- 655 *cynomolgi* and *Plasmodium knowlesi*. J Infect Dis [Internet]. 2019;219(5):695–702. Available
- 656 from: <u>https://www.ncbi.nlm.nih.gov/pubmed/30295822</u>
- 657 46. Putaporntip C, Kuamsab N, Seethamchai S, Pattanawong U, Rojrung R, Yanmanee S, et
- al. Cryptic *Plasmodium inui* and *Plasmodium fieldi* Infections Among Symptomatic Malaria
- 659 Patients in Thailand. Clin Infect Dis. 2021;75(5):805–12.
- 660 47. Marchand RP, Culleton R, Maeno Y, Quang NT, Nakazawa S. Co-infections of
- 661 Plasmodium knowlesi, P. falciparum, and P. vivax among Humans and Anopheles dirus
- 662 Mosquitoes, Southern Vietnam Volume 17, Number 7—July 2011 Emerging Infectious
- 663 Diseases journal CDC. Emerg Infect Dis. 2011;17(7):1232–9.

664

665

666

667

668

669



Figure 1. Limit of detection workflow for (A) *P*. genus, (B) *Plasmodium* species-specific, and (C) *P*. genus dried blood spot PCR assays

Abbreviations: DBS = dried blood spot; LOD = limit of detection; qPCR = real-time quantitative PCR; Pk = P. *knowlesi*; Pf = P. *falciparum*, Pv = P. *vivax*; Pcyn = P. *cynomolgi*; RT = reverse transcription



Figure 2. The median LOD and fold-change with and without reverse transcription for PCR assays to detect *Plasmodium* species.

(A) The median LOD (parasites/µL) for *P*. genus assays using 6 clinical isolates (*P. knowlesi*=4, *P. vivax*=1, *P. cynomolgi*=1) and *P. knowlesi*-specific assays using 4 clinical isolates; (B) The LOD (parasites/µL) for *P. vivax* (n=1) and *P. cynomolgi* (n=1) specific assays. Abbreviations: Pgenus, *Plasmodium* genus; Pk, *P. knowlesi*; Pv, *P. vivax*; Pc, *P. cynomolgi*